Tafasitamab Active Not Recruiting Phase 3 Trials for Marginal Zone Lymphoma (MZL) / Follicular Lymphoma ( FL) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04680052A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.